BioMimetic Therapeutics, Inc. Submits Augment®Bone Graft PMA Amendment to FDA
Published: Jul 10, 2012
FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that it has submitted to the Food and Drug Administration (FDA) an amendment to its Pre-Market Approval (PMA) application for Augment® Bone Graft for its use as an alternative to autograft in hindfoot and ankle fusion procedures. The amendment provides supplemental information requested by the FDA in a post-panel response letter announced by the Company earlier this year.